- Home
- NEWP vs XERS Comparison
NEWP vs XERS Comparison
Compare NEWP & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEWP | XERS |
|---|---|---|
| Founded | 1972 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.3M | 1.0B |
| IPO Year | 2006 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NEWP | XERS |
|---|---|---|
| Price | $4.24 | $6.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $6.00 | ★ $10.83 |
| AVG Volume (30 Days) | 1.0M | ★ 1.4M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | N/A | $34.37 |
| Revenue Next Year | N/A | $22.86 |
| P/E Ratio | ★ N/A | $618.00 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $1.31 | $4.30 |
| 52 Week High | $6.31 | $10.08 |
Technical Indicators
Market Signals| Indicator | NEWP | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 35.48 | 52.88 |
| Support Level | $3.31 | $5.81 |
| Resistance Level | $4.70 | $6.42 |
| Average True Range (ATR) | 0.30 | 0.22 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 6.22 | 72.00 |
Price Performance
Historical ComparisonAbout NEWP New Pacific Metals Corp.
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.